Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for AMBRISENTAN
- Ambrisentan Sotagliflozin and Prevention of Renal Injury; a Randomized Evaluation
- Efficacy and Safety Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension
- Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH
- Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension
- A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19
- Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis COVID-19
- Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial Hypertension
- Effects of Endothelin Receptor Antagonist on Ischemic Kidney Injury During Nephron Sparing Surgery
- mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms
- Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants
- A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis
- Upfront Combination Pulmonary Arterial Hypertension Therapy
- Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension
- Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension
- Mechanisms of Cerebrovascular Control
- Crossover Study From Macitentan or Bosentan Over to Ambrisentan
- The Role of Endothelin-1 in Sickle Cell Disease
- A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects
- Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH)
- The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study
- Ambrisentan for the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arterial Hypertension
- Ambrisentan in Single Ventricle
- The Effects of Ambrisentan on Exercise Capacity in Fontan Patients
- Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH)
- A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
- Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.
- Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)
- A Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High Altitude
- A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension
- Ambrisentan for Treatment of Portopulmonary Hypertension
- Examination of the Bronchoprotective Effect of Endothelin Receptor Blockade in Asthma
- The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers
- Drug Use Investigation for VOLIBRIS® (Ambrisentan) (Pulmonary Arterial Hypertension)
- Characterization and Detection of Prolonged Endothelin Receptors Antagonists Administration
- Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529
- An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH)
- Efficacy and Safety of Ambrisentan in Children 8-18yrs
- Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension
- Influence of Cytochrome CYP3A4-induction by St. John's Wort on the Steady State Pharmacokinetics of Ambrisentan
- A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses
- Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
- Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis
- Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet
- Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan
- A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
- ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis
- Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension
- Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan
- Study of Ambrisentan in Participants With Pulmonary Hypertension
- (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF
- A Study to Evaluate the Efficacy of an Oral Medication in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis (Scleroderma).
- Iloprost Power 15 in Pulmonary Arterial Hypertension
- An Observational Study For Ambrisentan
- Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)
- Pharmacogenomics in Pulmonary Arterial Hypertension
- A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)
- Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension
- A Study of GSK1325760A in Healthy Japanese Subjects
- Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension
- Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.
- Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.
- Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension
- ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)
Clinical trials list
click for details